Export

Sofosbuvir + velpatasvir
Essential medicine status
General description
A fixed-dose combination regimen of the direct acting antiviral agents sofosbuvir and velpatasvir for the treatment of genotypes 1-6 chronic hepatitis C virus (HCV) infection.
INN
Sofosbuvir + velpatasvir
Medicine type
Chemical agent
EML status history
First added in 2017 (TRS 1006) for Chronic hepatitis C
Added in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
  • Oral > Solid: 400 mg + 100 mg tablet